TSE:4568Pharmaceuticals
Daiichi Sankyo (TSE:4568): Valuation Insights After Breakthrough FDA Nod for R-DXd in Ovarian Cancer
If you have Daiichi Sankyo Company (TSE:4568) on your radar, the latest buzz is hard to ignore. The company, together with its partner Merck, has just received Breakthrough Therapy Designation from the U.S. FDA for its investigational drug raludotatug deruxtecan (R-DXd) in certain ovarian and related cancers after bevacizumab treatment. This regulatory milestone signals headway in bringing a new targeted option to patients who need it most and highlights real progress in Daiichi Sankyo's...